Sustained Codelivery of Cisplatin and Paclitaxel via an Injectable Prodrug Hydrogel for Ovarian Cancer Treatment
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
The sustained release of both the hydrophilic drug and hydrophobic drug from one delivery system remains challenging in pharmaceutics and biomaterials science. The combination of hydrophilic cisplatin and hydrophobic paclitaxel (PTX) exhibits a clinical survival advantage compared with the individual drug therapy against various tumors such as ovarian cancer. In this study, a localized, long-term codelivery system of cisplatin and PTX was developed using an injectable and thermosensitive polymer-platinum(IV) conjugate hydrogel as the carrier. The thermosensitive Bi(mPEG-PLGA)-Pt(IV) (PtGel) conjugate was synthesized via covalently linking two mPEG-PLGA copolymers onto a Pt(IV) prodrug, and its concentrated aqueous solution exhibited a reversible sol-gel transition upon heating. Meanwhile, the core-corona micelles formed by the amphiphilic conjugates in water could serve as a reservoir for the solubilization of PTX, and thus an injectable binary drug-loaded hydrogel formulation was obtained. We also found that the introduction of PTX into the conjugate hydrogel decreased its sol-gel transition temperature and improved its gel strength. In vitro release experiments showed that both of the loaded drugs were released in a sustained manner for as long as 2.5 months, which was the longest combination delivery of these two drugs ever reported. In vitro cellular assays revealed that the dual-drug system exhibited a synergistic anticancer effect against ovarian cancer cells. Finally, using the SKOV-3 ovarian cancer xenograft mouse model, we demonstrated that a single injection of the PTX-loaded conjugate hydrogel system resulted in enhanced anticancer efficacy and significantly reduced the side effects, when compared with the multiple injections of the free drug combination.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several prior studies have reported the nanoformulations simultaneously containing PTX and cisplatin, including formulations based on polymeric micelles formed by amphiphilic block copolymers [26–28], mesoporous carbon-silica nanospheres [29], and prodrug hydrogels [30].”
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Kinetic modeling on drug release from controlled drug delivery systems.
Dash, S., Murthy, P. N., Nath, L., & Chowdhury, P. (2010) · PubMed · Cited by 2,733
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Injectable hydrogels as unique biomedical materials
Yu, L., & Ding, J. (2008) · Chemical Society Reviews · doi:10.1039/b713009k · Cited by 1,545
Self-citationDirect Cellular Responses to Platinum-Induced DNA Damage
Jung, Y., & Lippard, S. J. (2007) · Chemical Reviews · doi:10.1021/cr068207j · Cited by 1,391
Paclitaxel and its formulations
Singla, A. K., Garg, A., & Aggarwal, D. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00986-3 · Cited by 1,100
Hydrogels for Protein Delivery
Vermonden, T., Censi, R., & Hennink, W. E. (2012) · Chemical Reviews · doi:10.1021/cr200157d · Cited by 1,091
Synergistic drug combinations tend to improve therapeutically relevant selectivity
Lehár, J., Krueger, A. S., Avery, W., Heilbut, A. M., Johansen, L. M., Price, E. R., Rickles, R. J., Short III, G. F., Staunton, J. E., Jin, X., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1549 · Cited by 938
Greco, F., & Vicent, M. J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.05.006 · Cited by 652
Kolishetti, N., Dhar, S., Valencia, P. M., Lin, L. Q., Karnik, R., Lippard, S. J., Langer, R., & Farokhzad, O. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011368107 · Cited by 565
Research works printed but not linked: 2
- Hayashi T., 2006, Gan to Kagaku Ryoho, 33, 1167
- Dash S., 2010, Acta Pol. Pharm., 67, 217
Cited by
Items 101–138 of 138
Xu, L., Tang, S., Yang, H., Liang, M., Ren, P., Wei, D., He, J., Kong, W., Liu, P., & Zhang, T. (2022) · Journal of Materials Chemistry B · doi:10.1039/d1tb02858h · Cited by 16
Polymeric Matrix-Based Nanoplatforms toward Tumor Therapy and Diagnosis
Zhu, H., Loh, X. J., Ye, E., & Li, Z. (2021) · ACS Materials Letters · doi:10.1021/acsmaterialslett.1c00558 · Cited by 15
Platinum-based drugs and hydrogel: a promising anti-tumor combination
Yao, J., Song, S., Zhao, H., & Yao, Y. (2023) · Drug Delivery · doi:10.1080/10717544.2023.2287966 · Cited by 14
“…copolymers self-assembled into hydrogels thermally in micelle formations and could release platinum(iv) for up to two months (Shen et al., 2015; Shen et al., 2017). in another supramolecular thermosensitive hydrogel based on diblock copolymers poly(ethylene glycol)-poly(N-phenylglycine)…”
BackgroundYang, X., Zhang, L., Zheng, L., Wang, Y., Gao, L., Luo, R., Li, X., Gong, C., Luo, H., & Wu, Q. (2022) · Journal of Materials Chemistry B · doi:10.1039/d1tb01904j · Cited by 13
Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery
Xiao, X., Oswald, J. T., Wang, T., Zhang, W., & Li, W. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181105115849 · Cited by 13
Engineering Nanoparticles for Gynecologic Cancer Therapy
Murray, A. M., Swingle, K. L., & Mitchell, M. J. (2025) · ACS Nano · doi:10.1021/acsnano.5c07748 · Cited by 14
Metal substrate catalysis in the confined space for platinum drug delivery
Velasco‐Lozano, S., Castro, S. A., Sánchez-Cano, C., Benítez‐Mateos, A. I., López‐Gallego, F., & Salassa, L. (2021) · Chemical Science · doi:10.1039/d1sc05151b · Cited by 11
Alam, M. N., Yu, J., Beale, P. J., & Huq, F. (2019) · Synergy · doi:10.1016/j.synres.2019.100060 · Cited by 11
Precise Ratiometric Drug Delivery for the Treatment of Triple-Negative Breast Cancer
Kang, R. H., Rasoulianboroujeni, M., Kianpour, M., Repp, L., Ponik, S. M., & Kwon, G. S. (2025) · ACS Nano · doi:10.1021/acsnano.5c13083 · Cited by 12
Advancements in Hydrogel-Based Therapies for Ovarian Cancer: A Review
Chen, B., & Liu, J. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01483-7 · Cited by 11
“Consequently, a potential hydrogel system for the simultaneous delivery of cisplatin and PTX has been developed [66].”
Xiao, L., Yang, H., Lü, Q., & Kaplan, D. L. (2024) · Macromolecular Bioscience · doi:10.1002/mabi.202300523 · Cited by 10
Innovative landscapes in intraperitoneal therapy of ovarian cancer
Kumar, K., Madhusoodanan, M. S., Pangath, M., & Menon, D. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01765-w · Cited by 11
“A single injection of this matrix resulted in enhanced anti-cancer efficacy in SKOV-3 xenograft mouse models with reduced side effects, when compared to multiple injections of the free drug combination [97].”
Research Strategies and Methods of Hydrogels for Antitumor Drug Delivery
Zeng, T., Chen, L., Yoshitomi, T., Kawazoe, N., Yang, Y., & Chen, G. (2025) · Biomedicines · doi:10.3390/biomedicines13081899 · Cited by 10
“Although PTX showed a slower release rate than that of CDDP, both drugs maintained a steady release profile throughout the study, contributing to enhanced antitumor efficacy through sustained therapeutic concentrations at the tumor site [139].”
Santhosh, S., Nanjan, M. J., & Chandrasekar, M. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.03.018 · Cited by 8
Li, J., Zhao, J., Chen, Y., Zheng, Y., Zhou, L., Zhao, J., Liu, Y., Liu, X., & Wang, S. (2020) · Science China Technological Sciences · doi:10.1007/s11431-020-1623-8 · Cited by 8
Advanced drug delivery systems in the treatment of ovarian cancer
Padhi, S., & Behera, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85503-7.00020-1 · Cited by 9
Yan, B., Gu, L., Zafar, H., Shi, A., Ge, H., Jin, Y., Wang, N., Wang, M., Liu, B., Wu, Y., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1681276 · Cited by 7
Liu, B., Liu, Z., Wang, P., Zhang, Y., He, H., Yin, T., Gou, J., & Tang, X. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.110229 · Cited by 5
Injectable hydrogel: A promising frontier in cancer therapy
Farajollahi, A. (2025) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2025.12.002 · Cited by 8
In situ gels for postoperative cancer treatment: Current status and challenges
Ye, Z., Li, Y., Luo, X., Xue, K., Liang, L., Meng, Z., Zhu, P., Li, Y., & Huang, H. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.159621 · Cited by 7
Xu, H., Zhang, X., Kang, L., Feng, S., Li, Y., & Zhao, G. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.140143 · Cited by 6
Jin, Y., Sun, P., Wu, T. S., Wang, J., Huang, X., Zuo, S., Cui, Z., Chen, J., Li, L., Suo, N., et al. (2021) · Journal of Nanomaterials · doi:10.1155/2021/9956466 · Cited by 5
“Anticancer drug (cis-platinum) has been widely used as a chemotherapy medication to treat many cancers [24, 25].”
BackgroundKAUSHIK, K. K., & Tiwari, S. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126045 · Cited by 6
Wen, C., Park, J., Jikaria, N. R., Landmesser, M. E., Dawes, J., Wu, C., Ravnic, D. J., & Wang, Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114251 · Cited by 4
A systematic review of emerging technologies to enhance the treatment of ovarian cancer
Sepahi, S., Kiaei, L., Kiaei, M., & Ghorani‐Azam, A. (2023) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2023.2233588 · Cited by 4
Nanocarrier Delivery of Cisplatin and its Patent Studies
Kumar, M., Sharma, S., Bhatnagar, P., Tejaswi, & Banik, B. K. (2024) · Current Nanomedicine · doi:10.2174/0124681873332471241022152313 · Cited by 3
Guo, Z., Jiang, X., Zhang, Y., & Zhu, Y. (2025) · New Journal of Chemistry · doi:10.1039/d4nj05316h · Cited by 2
Jiao, L., Li, M., Tan, M., ZHENG, L., Liu, Y., & Cao, Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s603950 · Cited by 3
Magic shotgun over magic bullet for treatment of ovarian cancer via polymeric nanoparticles
Ahmed, B., Sharma, A., Usmani, Z., Sharma, G., Singh, J., Yadav, R., Sharma, I., & Kaur, I. P. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104945 · Cited by 3
Le, T. P., Kim, S. J., Jin, S., Shin, S.-A., Kim, S., Kim, D., Park, Y.-H., & Huh, K. M. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115017 · Cited by 1
Advances in cisplatin-driven drug delivery systems: Enhancing anticancer efficacy and safety
Wang, Z., Yang, J., Chen, M., Duan, C., Sun, H., Wei, S., Liu, J., & Yu, S. (2026) · Precision medicine and engineering. · doi:10.1016/j.preme.2026.100083 · Cited by 1
Hydrogels for cancer treatment
Ribeiro, V. P., Silva‐Correia, J., Reis, R. L., & Oliveira, J. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823948-3.00016-6 · Cited by 1
Development of Chloroquine-containing HPMA Copolymers for Drug Delivery
Yu, F. (2018) · DigitalCommons@UNMC
Li, P., & Lou, Y. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/2782875
In Situ-Forming Hydrogels for Intratumoral Drug Delivery
Marques, A. C., Costa, P. C., Velho, S., & Amaral, M. H. (2026) · Springer eBooks · doi:10.1007/978-981-95-6619-8_7
Integrated DoE strategy for the development of low-release hydrogels
Nadeau, C., Dhondt, S., Moawad, F., & Brambilla, D. (2026) · Chemical Communications · doi:10.1039/d6cc03410a
Wang, C., Xiu, Y., Zhang, Y., Xu, J., Wang, Y., & Xing, D. (2026) · Antioxidants · doi:10.3390/antiox15091214
Fan, F., Liu, Y., Petrosini, G., Cruz-Gonzalez, B., Kaliney, W., Awasthi, N., Stack, M. S., & Hanjaya‐Putra, D. (2026) · Acta Biomaterialia · doi:10.1016/j.actbio.2026.10.055
Metadata
- Authors
- Shen, W., Chen, X., Luan, J., Wang, D., Yu, L., & Ding, J.
- Affiliations
- Fudan University (CN)
- Corresponding author
- Yu, Lin
- Venue
- ACS Applied Materials & Interfaces
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-11-13
- Volume
- 9
- Issue
- 46
- Pages
- 40031-40046
- ISSN
- 1944-8244 (ISSN-L)
- 1944-8252
- OpenAlex
- W2770498164
- Cited by
- 138
- References
- 65
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 8 · 2023: 17 · 2022: 15 · 2021: 20 · 2020: 17 · 2019: 21 · 2018: 16
- FWCI
- 5.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- ACS Applied Materials & Interfaces (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Science and Technology of the People's Republic of China (2016YFC1100300)
- National Natural Science Foundation of China (21474019, 51273217)
- Science and Technology Developing Foundation of Shanghai (15JC1490300)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Hydrogels: synthesis, properties, applications
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- cisplatin, paclitaxel, ovarian cancer, co-delivery, injectable hydrogel, thermosensitive hydrogel, platinum(IV) prodrugs, sol-gel transition, sustained drug release, combination chemotherapy, synergistic antitumor effect, SKOV3 xenograft
- MeSH terms
- Animals, Cisplatin, Drug Carriers, Female, Micelles, Ovarian Neoplasms, Polyethylene Glycols, Prodrugs, Drug Delivery Systems, Paclitaxel, Hydrogels, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.